6XY Stock Overview
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.14 |
| 52 Week High | HK$0.20 |
| 52 Week Low | HK$0.097 |
| Beta | 1.47 |
| 1 Month Change | 6.98% |
| 3 Month Change | -11.54% |
| 1 Year Change | -27.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 25.5% | 1.8% | -0.3% |
| 1Y | -27.4% | -19.9% | 2.8% |
Return vs Industry: 6XY underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 6XY underperformed the German Market which returned 2.8% over the past year.
Price Volatility
| 6XY volatility | |
|---|---|
| 6XY Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XY's share price has been volatile over the past 3 months.
Volatility Over Time: 6XY's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 177 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9378 for the treatment of Asthma; and HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors.
HBM Holdings Limited Fundamentals Summary
| 6XY fundamental statistics | |
|---|---|
| Market cap | €123.68m |
| Earnings (TTM) | €21.19m |
| Revenue (TTM) | €83.21m |
5.8x
P/E Ratio1.5x
P/S RatioIs 6XY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XY income statement (TTM) | |
|---|---|
| Revenue | US$89.50m |
| Cost of Revenue | US$2.03m |
| Gross Profit | US$87.47m |
| Other Expenses | US$64.67m |
| Earnings | US$22.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.031 |
| Gross Margin | 97.73% |
| Net Profit Margin | 25.47% |
| Debt/Equity Ratio | 53.8% |
How did 6XY perform over the long term?
See historical performance and comparison